Podcasts about Eli Lilly

AI data wars push Reddit to block the Wayback Machine China Launches Three-Day Robot Olympics Featuring Football and Table Tennis US government agency drops Grok after MechaHitler backlash, report says Eli Lilly signs $1.3 billion deal with Superluminal to use AI to make obesity medicines The AI Was Fed Sloppy Code. It Turned Into Something Evil. | Quanta Magazine AI data centers made Americans' electricity bills 30% higher Sam Altman says 'yes,' AI is in a bubble Is the A.I. Sell-off the Start of Something Bigger? Thousands of Grok chats are now searchable on Google Opinion | Amy Klobuchar: I Knew A.I. Deepfakes Were a Problem. Then I Saw One of Myself. 2,178 Occult Books Now Digitized & Put Online, Thanks to the Ritman Library and Da Vinci Code Author Dan Brown Pluralistic: "Privacy preserving age verification" is bullshit (14 Aug 2025) How to use "skibidi" and other new slang added to Cambridge Dictionary YouTube Is Making a Play to Host the Oscars Leobait: Resisting AI Solutionism through Workplace Collective Action So ... is AI writing any good? Project Indigo We used AI to analyse three cities. It's true: we now walk more quickly and socialise less Hosts: Leo Laporte, Jeff Jarvis, and Paris Martineau Guest: Rich Skrenta Download or subscribe to Intelligent Machines at https://twit.tv/shows/intelligent-machines. Join Club TWiT for Ad-Free Podcasts! Support what you love and get ad-free shows, a members-only Discord, and behind-the-scenes access. Join today: https://twit.tv/clubtwit Sponsors: pantheon.io helixsleep.com/twit

This Day in Legal History: Nineteenth Amendment RatifiedOn August 18, 1920, the Nineteenth Amendment to the U.S. Constitution was ratified, guaranteeing women the right to vote and marking a major legal milestone in the struggle for gender equality. The amendment states simply: “The right of citizens of the United States to vote shall not be denied or abridged… on account of sex.” Its passage capped off more than 70 years of organized activism, dating back to the Seneca Falls Convention in 1848. Suffragists like Susan B. Anthony, Elizabeth Cady Stanton, Sojourner Truth, and Alice Paul played pivotal roles in maintaining momentum across generations, despite fierce opposition.The road to ratification was grueling. Congress passed the amendment in 1919, but it still required approval from three-fourths of the states—36 at the time. Tennessee became the critical 36th state, narrowly approving the amendment in a dramatic vote where a 24-year-old legislator, Harry T. Burn, changed his vote after receiving a letter from his mother urging him to support suffrage. That moment tipped the scales and enshrined the right to vote for women nationwide.Before the amendment, several western states had already extended suffrage to women, but many others actively suppressed it. The legal recognition of women's voting rights through constitutional amendment removed any ambiguity and forced all states to comply. The Nineteenth Amendment not only transformed the electorate but also reshaped American democracy by recognizing women as full political participants.The Trump administration is accusing a federal judge in Boston of undermining the authority of the U.S. Supreme Court by continuing to block the administration from firing staff in the Department of Education's Office for Civil Rights. U.S. District Judge Myong Joun had issued an injunction requiring the reinstatement of employees let go in a mass layoff, despite the Supreme Court having recently paused a broader version of that order. The Justice Department has asked the 1st U.S. Circuit Court of Appeals to intervene, arguing that Joun's refusal to lift the narrower injunction contradicts the Supreme Court's ruling and undermines the rule of law.The judge's decision stems from a lawsuit challenging Secretary of Education Linda McMahon's plan to lay off over 1,300 department employees, part of President Trump's broader goal of eliminating the department—something only Congress can authorize. The plaintiffs, including students and advocacy groups, focused specifically on the Office for Civil Rights, which was set to lose half its staff. They argue that lifting the injunction now would effectively reward the administration's ongoing failure to comply with the court's order, as the terminated employees have not yet been reinstated.Judge Joun, appointed by President Biden, criticized the Supreme Court's ruling as "unreasoned" and pointed to the administration's continued noncompliance. The 1st Circuit has asked the plaintiffs to respond promptly to the Justice Department's request, signaling an expedited review.Trump administration claims judge defied Supreme Court to bar Education Department firings | ReutersFederal Reserve Chair Jerome Powell is preparing for what may be his final speech at the annual Jackson Hole conference, facing a complicated economic picture that challenges his data-driven policy approach. In past years, Powell used the conference to pledge aggressive action against inflation and, later, to support the labor market. Now, with inflation still above target and signs of economic slowdown emerging, Powell must decide whether to prioritize price stability or job preservation.The Trump administration and many investors expect interest rate cuts at the Fed's September meeting, but Powell's messaging—how he frames future actions—may matter more than the decision itself. Internally, Fed officials are split: some want to move quickly to protect jobs, while others want to wait for clearer evidence that inflation won't rebound. Powell has previously styled himself after past Fed chairs like Paul Volcker and Alan Greenspan, with Volcker's inflation-fighting resolve and Greenspan's forward-looking leniency both offering competing models.Recent economic data has sent mixed signals. Revised job growth numbers were lower than initially reported, supporting arguments for easing monetary policy, but inflation has edged up again. Trump's tariff policies add further uncertainty, though their economic impact has so far been less severe than feared. With the economy growing slowly and inflation still above the Fed's 2% target, Powell must decide whether to stay the course, cut rates cautiously, or begin a broader shift.Powell has used Jackson Hole to battle inflation and buoy jobs; he's now caught between both | ReutersNovo Nordisk's shares rose by up to 5% after receiving accelerated U.S. approval for its weight-loss drug Wegovy to treat MASH (metabolic dysfunction-associated steatohepatitis), a progressive liver disease that affects about 5% of U.S. adults. This marks the first GLP-1 drug approved for MASH and offers a significant, if temporary, advantage over competitor Eli Lilly, which is still in clinical trials for its own MASH-targeting drug, tirzepatide.The news was a welcome reversal for Novo, which recently lost over $70 billion in market value following a profit warning and leadership change. The company, once Europe's most valuable publicly traded firm due to Wegovy's success, has seen its share price drop sharply over the past year amid intensifying competition in the obesity drug market and the rise of compounded copycat drugs.Although Novo now holds a short-term lead in the liver disease market, analysts expect that exclusivity will be brief once Eli Lilly gains approval. Novo has also submitted applications in Europe and Japan, signaling its intention to secure broader global use for Wegovy beyond weight loss.Shares in Novo Nordisk rise after Wegovy gets US nod for liver disease treatment | ReutersNorton Rose's ambitious tech partnership with NMBL Technologies has ended in failure and mutual lawsuits, highlighting how difficult it is for Big Law firms to pivot from selling legal services to selling tech products. The firm's Chicago office, launched in 2022 as an “innovation hub,” aimed to introduce 150 clients to Proxy, a legal workflow tool developed by a new partner, Daniel Farris. But three years later, not a single sale was made. NMBL claims Norton Rose didn't uphold its end of the deal and stifled the rollout, while the firm says clients weren't interested and is seeking damages for the investment.The fallout underscores broader challenges law firms face as they increasingly invest in artificial intelligence and legal tech amid growing demand and rising budgets. Unlike traditional legal work, selling products requires different infrastructure and skills—such as dedicated sales teams—that most law firms lack. Despite producing marketing materials and training resources, NMBL alleges that very few Norton Rose lawyers engaged with the product and that the firm failed to meaningfully promote it.NMBL is seeking $15 million in damages, accusing the firm of using the deal merely to recruit talent, while Norton Rose wants $250,000, calling the product commercially nonviable. The firm also allegedly created a shell subsidiary, LX, to meet contract terms but never properly funded or activated it. This case illustrates the steep learning curve law firms face in transitioning to tech-based business models and the internal resistance that can derail innovation.Firm's Failed Tech Venture Foretells Big Law's AI Sales Struggle This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe

In der heutigen Folge sprechen die Finanzjournalisten Lea Oetjen und Holger Zschäpitz über Börsen-Non-Event Alaska, eine hoffnungsvolle Softwarestudie mit 6 Top Picks und einen neuen Chart of Doom. Außerdem geht es um CoreWeave, Salesforce, Siemens Energy, Cisco Systems, Palo Alto Networks, ProSiebenSat.1, Novo Nordisk, AstraZeneca, AbbVie, Siemens Healthineers, Sonova, Medtronic, Haleon, iShares Aging Population ETF (WKN: A2ANH1), Boston Scientific, Glaukos, Exelixis, Sarepta, Swisscanto Healthy Longevity Fund (WKN: A40L0T), Eli Lilly, Abbott, UnitedHealth, Microsoft, Amazon, Nvidia, Meta, Netflix, Coreweave, Oracle, Carvana, TSMC, Roblox, Crowdstrike, Opendoor Technologies, Alibaba, PDD, Petroleo Brasileiro, Teva Pharmaceutical, Robinhood, Northrop Grumman, RTX, Lululemon, Mercadolibre, Talen Energy, GE Vernova, Broadcom, Vistra, Micron, Alphabet, Somnigroup International, Flutter Entertainment. Und hier gibt es die Tickets zum Finance Summit am 17. September! https://veranstaltung.businessinsider.de/FinanceSummit Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

 It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: cancer reserach may lead to T1D treatment, GLP-1 oral pill moves forward, Tandem pharmacy moves, Medtronic-Abbott sensor unveield, parents of kids with T1D see income drop, Mannkind submits Afrezza for pediatrics, diabetes scholarships and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Cornell researchers have developed an implant system that can treat type 1 diabetes by supplying extra oxygen to densely packed insulin-secreting cells, without the need for immunosuppression. The system could also potentially provide long-term treatment for a range of chronic diseases. This lab has produced previous implantable devices that have proved effective in controlling blood sugar in diabetic mice, but they can only last so long. "It's the proof of concept. We really proved that oxygenation is important, and oxygenation will support high cell-density capsules," Tempelman said. "The capsules are immune protective and last for a long time without having some kind of fouling of the membrane. The body never likes it when you put a foreign substance in. So that's the engineering in the Ma Lab, to look for materials and coatings for the materials that are immune protective, but also don't invoke excess response from the body because of the material." The next step will be to implant the system in a pig model, and also test it with human stem cells. The researchers are interested in eventually trying to use the system for implanting different cell types in humans for long-term treatment of chronic diseases, according to Tempelman, who is CEO of Persista Bio Inc., a new startup she founded with Ma and Flanders that is licensing these technologies. https://medicalxpress.com/news/2025-08-implant-diabetes-oxygenating-insulin-cells.html XX Mayo Clinic cancer research may be big news for T1D. After identifying a sugar molecule that cancer cells use on their surfaces to hide from the immune system, the researchers have found the same molecule may eventually help in the treatment of type 1. Cancer cells use a variety of methods to evade immune response, including coating themselves in a sugar molecule known as sialic acid. The researchers found in a preclinical model of type 1 diabetes that it's possible to dress up beta cells with the same sugar molecule, enabling the immune system to tolerate the cells. The findings show that it's possible to engineer beta cells that do not prompt an immune response   In the preclinical models, the team found that the engineered cells were 90% effective in preventing the development of type 1 diabetes. The beta cells that are typically destroyed by the immune system in type 1 diabetes were preserved.     https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-researchers-find-sugar-coating-cells-can-protect-those-typically-destroyed-in-type-1-diabetes/ XX A daily pill may be as effective in lowering blood sugar and aiding weight loss in people with Type 2 diabetes as the popular injectable drugs Mounjaro and Ozempic, according to results of a clinical trial announced by Eli Lilly on Thursday morning.   The drug, orforglipron, is a GLP-1, a class of drugs that have become blockbusters because of their weight-loss effects. But the GLP-1s on the market now are expensive, must be kept refrigerated and must be injected. A pill that produces similar results has the potential to become far more widely used, though it is also expected to be expensive.   Lilly said it would seek approval from the Food and Drug Administration later this year to market orforglipron for obesity and early in 2026 for diabetes. https://www.nytimes.com/2025/04/17/health/pill-glp-1-eli-lilly.html XX Use of diabetes technology has dramatically increased and glycemic control has improved among people with type 1 diabetes (T1D) in the US over the past 15 years, but at the same time, overall achievement of an A1c level < 7% remains low and socioeconomic and racial disparities have widened. These findings came from an analysis of national electronic health records of nearly 200,000 children and adults with T1D by Michael Fang, PhD, of the Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, and colleagues. The study was published online on August 11, 2025, in JAMA Network Open. Use of continuous glucose monitors (CGMs) increased substantially from 2009-2011 to 2021-2023, from less than 5% in both children and adults to more than 80% and over half, respectively. While A1c levels did drop over the 15 years, just 1 in 5 children and slightly over a quarter of adults achieved a level < 7%. The average A1c level stayed above 8%, with ethnic minorities and low-income patients seeing the smallest gains.       https://www.medscape.com/viewarticle/diabetes-tech-use-rise-a1c-reductions-still-lag-2025a1000lc9 XX Inflammation may predict how well people with diabetes respond to depression treatment, and the effects differ dramatically between type 1 and type 2 diabetes. Diabetes and depression often appear together. Indeed, depression is more than three times more prevalent in people with type 1 diabetes (T1D) and nearly twice as prevalent in people with type 2 diabetes (T2D). When they appear together, treatment for depression can vary widely. In a new study, researchers from the German Diabetes Center (DDZ), the Research Institute of the Diabetes Academy Mergentheim (FIDAM), and the German Center for Diabetes Research (DZD) investigated how inflammation in the body relates to improvement in depression symptoms in people with T1D and T2D. The researchers combined data from three previous German randomized clinical trials that aimed to reduce elevated depressive symptoms and diabetes distress in people with type 1 or type 2 diabetes. Diabetes distress is characterized by feelings of overwhelm, frustration, guilt and worry about diabetes management and its potential complications. A total of 332 participants with T1D and 189 with T2D who had completed both a baseline and 12-month follow-up examination were included in the present study. Measures included depression using the Center for Epidemiological Studies Depression scale (CES-D), blood tests for 76 inflammatory biomarkers, and symptoms broken down into cognitive-affective (e.g., feeling hopeless), somatic (e.g., poor sleep, fatigue), and anhedonia (loss of pleasure) clusters.   After adjusting for factors like age, body mass index (BMI), diabetes duration, cholesterol, and co-existing illnesses, the researchers found that in patients with T1D, higher baseline inflammation was linked to smaller improvements in depression. Inflammation seemed to be more connected to physical/somatic symptoms in T1D patients. In those with T2D, higher baseline inflammation was linked to greater improvements in depression. For these patients, the effect was strongest for cognitive-affective and anhedonia – so, emotional and motivational – symptoms.   The researchers weren't sure what caused the difference between T1D and T2D, but they suggest it might be due to the different forms of immune activation seen in each condition. That is, autoimmune processes in type 1 and metabolic inflammation in type 2. https://newatlas.com/health-wellbeing/inflammation-diabetes-depression-treatment/ XX Parents of children diagnosed with type 1 diabetes suffer an income drop in the years following the diagnosis. The impact is more pronounced in mothers, especially mothers of children diagnosed in preschool years. And these findings come from a European study.. not the US. Previous research has shown that parents of children with type 1 diabetes are at increased risk of stress-related symptoms and may need to reduce their working hours. "In our study, we observed reduced parental work-related incomes in the years following the child's type 1 diabetes diagnosis. The drop was larger in mothers than in fathers. Since mothers earned significantly less than fathers in absolute terms, even before the child fell ill, the relative drop in mothers was 6.6% the year following diagnosis compared to 1.5% in fathers. We further note the greatest impact on work-related incomes in mothers of children diagnosed at preschool age," says Beatrice Kennedy, physician at the Endocrine and Diabetes unit at Uppsala University Hospital and Associate Professor of Medical Epidemiology at Uppsala University, who led the study. This is a huge study, builds on data from national population and health registers and the Swedish Child Diabetes Register (Swediabkids). The study includes the parents of more than 13,000 children diagnosed with type 1 diabetes in Sweden in 1993−2014, as well as more than half a million parents in the general population who have children not diagnosed with diabetes.   The researchers observed that the maternal pension-qualifying incomes (a composite outcome including work-related income and societal benefits) initially increased after the child's diagnosis. This was attributable to mothers applying for the parental care allowance from the Swedish Social Insurance Agency. The parental care allowance was intended to compensate for disease-related loss of work-related income and contribute toward disease-specific costs.   When the research team investigated long-term effects in mothers, they found that the pension-qualifying incomes gradually decreased after eight years, and had not recovered by the end of follow-up − 17 years after the children were diagnosed. https://www.news-medical.net/news/20250811/Mothers-face-greater-financial-impact-following-childe28099s-type-1-diabetes-diagnosis.aspx XX The U.S. Department of Justice has reached a settlement with Metro Nashville Public Schools after allegations that the district violated the Americans with Disabilities Act.   The parents of a student at the Ross Early Learning Center requested that the school monitor their child's glucose monitor. Investigators found the school refused to do so, despite the child's Type 1 Diabetes diagnosis.   As part of the settlement, MNPS agreed to change its policies to allow the use of these devices, ensure trained staff can monitor them throughout the entire school day and at school activities, and improve communication with parents. https://www.wsmv.com/2025/08/12/metro-nashville-public-schools-settles-allegations-it-discriminated-against-students-with-diabetes/ XX Modular Medical has unveiled Pivot, its next-generation insulin patch pump technology aimed at simplifying diabetes care. The company announced its new pump for “almost-pumpers” at the Association of Diabetes Care & Education Specialists (“ADCES”) Conference in Phoenix, Arizona this weekend. It aims for Pivot to target adults with a user-friendly, affordable design.   Modular Medical's current pump, the MODD1, won FDA clearance nearly a year ago. It features new microfluidics technology to allow for the low-cost pumping of insulin. The system has a reservoir size of 300 units/3mL. Users can monitor the pump activity with their cell phone and do not require an external controller. The pump uses a provided, single-use, disposable battery.   The company announced recently that it validated its insulin pump cartridge line for human-use production in the U.S. Days later, it reported the first human use of the MODD1 pump.   Now, it has taken the next steps with the debut of a next-gen pump, set for FDA submission in October.   Modular Medical also gamifies diabetes care The company also said ADCES is the place where it will showcase the first playable level of its new Pivot pump gamified trainin module. Level Ex, a developer of medical games, develops the module.   Modular Medical said gamification offers a way to make medical training more effective and efficient while improving information retention. Given the complexity in pump uptake, the company hopes to provide an easy way to bring its technology to clinicians and patients.   The company expects to have training modules available at the same time as the pump's planned launch in 2026.   “Level One is free because diabetes mastery shouldn't come with a price tag,” Sam Glassenberg, CEO of Level Ex, said. “Modular Medical is breaking barriers too – bringing pump therapy to more people through smart, accessible design. Together, we intend to make diabetes management simpler and more inclusive.   “People learn best through play – and we believe they want to learn about insulin pumps the same way. In Level One, players aren't just mastering diabetes management through gameplay – they're asking to ‘play' with pumps: to explore how they work, understand their benefits, and build confidence before using them in real life. Our partnership with Modular Medical helps make that possible.” https://www.drugdeliverybusiness.com/modular-medical-unveils-next-gen-insulin-pump/ XX On Tuesday, 12 August 2025, Tandem Diabetes Care (NASDAQ:TNDM) presented at the Canaccord Genuity's 45th Annual Growth Conference, outlining strategic shifts and market focus. The company highlighted its plans for commercial transformation in the U.S. and expansion in international markets, alongside addressing competitive challenges and regulatory impacts. While optimistic about growth in Outside the U.S. (OUS) markets, Tandem is navigating a more competitive landscape domestically. We have entered into the pharmacy channel with Mobi only. And so as Mobi's been building up volume, we're getting experience and we're really learning and understanding what pharmacy offers to us. And the proof points have proved out the thesis I said earlier, which is it can really reduce that barrier for patients, is the out of pocket cost. And so we've decided to accelerate our strategy and where we were starting just with Mobi, we are now moving t slim supplies into the pharmacy channel, and that will kick into gear in the fourth quarter. So as people are looking at the cadence of sales for the remainder of the year with this reframing, many folks are seeing what looks like a a might be an outsized fourth quarter and and having trouble understanding those dynamics. We'll be adding the tSIM supplies to those contracts. We also have more coverage. We will have it in the coming weeks effective this year, so we will be increasing that 30% rate before the end of the year. And then, obviously, everyone's in the same cycle right now already negotiating and discussing their 2026 coverage. And so 30% is the floor.   We do expect to continue to grow that coverage in the coming years, and ultimately have a much broader access. Absolutely. It's an exciting technology that allows for us to have an infusion set that extends the wear time from three days to up to seven days. So we're able to use that as part of an independent infusion set, which would then be used with the t slim and with the mobi pump today. But we're also using that same technology as part of the site that's used for mobi when you use it with a tubeless cartridge. So next year, we will launch Mobi in a patch configuration.   It uses the same pump that's available today, but by using a modified cartridge, you're able to wear it as a patch pump. So one of the things we announced on the call is that we're using this extended wear technology as part of that site. So what it allows you to do is to change the portion that you wear in your skin separate from the timing of when you change the insulin cartridge. So it allows for that extended wear time, reduction of burden to the patient, which is especially important for higher volume insulin users as we expand into type two. So from here, we will launch the extended wear site next year along with we'll do a separate regulatory filing for the cartridge portion for Mobi that includes this extended wear technology as a predicate device. So that's another filing that we'll need to do, but we have the clearance today for the independent infusion set, but we'll file another five ten k for use of the extended wear technology as part of the tubeless Mobi feature. https://za.investing.com/news/transcripts/tandem-diabetes-at-canaccord-conference-strategic-shifts-and-market-focus-93CH-3834464 XX MannKind today announced a significant regulatory submission and a large financing agreement with Blackstone. The company submitted its lead inhaled insulin product for expanded FDA approval and secured $500 million in funding, it said.   First, the Danbury, Connecticut-based company announced that it submitted a supplemental Biologics License Application (sBLA) for Afrezza, its inhaled insulin product, in the pediatric population.   MannKind Director of Medical and Scientific Engagement Joanne Rinker, MS, RDN, BC-ADM, CDCES, LDN, FADCES, told Drug Delivery Business News at ADA 2025 that a submission was on the way for children and adolescents aged 4-17 years old. Further data shared at ADA found Afrezza both safe and effective in that age range.   Afrezza is a fast-acting insulin formulation delivered through an inhaler device. MannKind engineered the mechanical inhaler device to slowly bring powder into the lung. A small compartment opens for the insertion of the insulin cartridge, then the user closes it. The only other component is a mouthpiece for the sake of cleanliness. Then, the inhalation takes just two seconds. It requires no electronics or extra components.   The company expects a review acceptance decision early in the fourth quarter of 2025.   “The submission of our supplemental Biologics License Application (sBLA) for Afrezza in pediatric patients is a meaningful milestone for MannKind and people living with diabetes,” said Michael Castagna, CEO of MannKind Corporation.   Additional funding provides a significant boost for MannKind MannKind also announced a strategic financing agreement with funds managed by Blackstone worth up to $500 million. The financing provides MannKind with non-dilutive capital to advance its short- and long-term growth strategies.   This senior secured credit facility includes a $75 million initial term loan funded at closing. It then has a $125 million delayed draw term loan available for the next 24 months. Finally, it features an additional $300 million uncommitted delayed draw term loan available at the mutual consent of MannKind and Blackstone.   The facility bears interest at a calculated SOFR variable rate plus 4.75% and matures in August 2030.   “This strategic financing significantly increases our operating flexibility and provides us substantial access to non-dilutive capital on favorable terms, complementing our strong cash position,” said Castagna. “The funding will support the expansion of our commercial team in preparation for the anticipated launch of the pediatric indication for Afrezza, if approved, continued pipeline advancement, potential business development opportunities, and general corporate purposes. Partnering with the Blackstone team on this transaction positions us to accelerate our next phase of growth and innovation.” https://www.drugdeliverybusiness.com/mannkind-fda-submission-pediatrics-500m-blackstone/ XX   Medtronic MiniMed Abbott Instinct Sensor [Image from Medtronic Diabetes on LinkedIn] The Medtronic Diabetes business today took to social media to share an early preview of a new integrated Abbott sensor for its insulin delivery systems. Medtronic Diabetes — soon to be MiniMed after its planned separation from the medtech giant – said in the post that the new sensor specifically designed for its own systems is called “Instinct.”   “Get a sneak peek at what's coming next: the Instinct sensor,” the business unit's account wrote. “Made by Abbott, the Instinct sensor is designed exclusively for MiniMed systems. We'll share more details about the Instinct sensor when it's commercially available.”   The sensor, built on the Abbott FreeStyle Libre platform, reflects “the power of the partnership,” Abbott EVP, Diabetes Care, Chris Scoggins, told Drug Delivery Business News earlier this year.   Medtronic and Abbott — two of the largest diabetes tech companies in the world — announced a year ago that they entered into a global partnership pairing Abbott continuous glucose monitors (CGMs) with Medtronic insulin delivery systems.   The partnership aims to collaborate on a system based on Abbott's FreeStyle Libre CGMs with Medtronic's automated insulin delivery technology (the latest generation being the MiniMed 780G) and smart insulin pen systems, such as the InPen system.   Read more about Medtronic, Abbott and the rest of the diabetes tech industry in our free Diabetes Technology Special Report. Medtronic's systems previously used its own CGMs, such as the Guardian 4 and the Simplera platform, and the company intends to continue using those systems as part of a comprehensive CGM portfolio. Under the companies' agreement, the systems would be sold exclusively by Medtronic — including the Abbott CGM.   The companies brought the partnership a step further in April when Medtronic announced the submission of an interoperable pump with the Abbott sensor technology to the FDA. They plan to share more details following the expected FDA clearance, which remains pending.   Management also recently emphasized the multi-year nature of the partnership, meaning Medtronic could pair current and future pumps with other Abbott sensors in the future. That could hint at integration with the company's future dual glucose-ketone monitor, as a number of pump makers have already announced collaborations to pair their systems with the sensor once it hits the market. https://www.drugdeliverybusiness.com/medtronic-diabetes-previews-abbott-sensor-minimed/ XX Governor Glenn Youngkin joined Civica officials at the company's Petersburg manufacturing facility to announce a $3 million grant from the Commonwealth of Virginia to accelerate Civica's efforts to develop and produce affordable insulin for Americans living with diabetes.   CivicaRx Logo   "We are proud to partner with Civica in their mission to make essential medicines more accessible," said Governor Youngkin. "This investment reflects our belief in the power of public-private collaboration to improve lives and strengthen communities."   These funds will support the production of insulin aspart, a rapid-acting human insulin analog used to regulate blood sugar in adults and children with diabetes. Civica plans to produce both rapid- and long-acting insulins at its state-of-the-art manufacturing facility in Petersburg, Va., where the company now employs more than 200 skilled workers.1 Over 8 million people living with diabetes need rapid-acting and/or long-acting insulin.   The Governor also announced that he had officially proclaimed August 7 – 14 2025 'Life Sciences Week' demonstrating the Commonwealth's commitment to "accelerating the advancement of the life sciences through public-private partnerships, STEM education, workforce development, and sustained investment in research and development."   "We are grateful for the Commonwealth's support," said Ned McCoy, Civica's President and CEO. "This funding will help us move closer toward our goal of ensuring that no one has to choose between insulin and other basic needs."   Civica and Virginia officials were joined by Lynn Starr, Chief Global Advocacy Officer of Breakthrough T1D, the leading global type 1 diabetes research and advocacy organization.   "More than one million American adults live with type 1 diabetes, and many still, sadly, ration their insulin, due to the prohibitively high cost of this necessary medication," said Starr.  "Civica's work will help to make insulin more affordable for people across the country."   Breakthrough T1D is among more than two dozen organizations and philanthropists, along with the states of Virginia and California, that have partnered with Civica to support the development of affordable insulins.   Civica's insulin initiative aims to provide patients with predictable, transparent pricing — no more than $30 per vial or $55 for a box of five pens — regardless of insurance status.   About Civica Civica is a nonprofit pharmaceutical company established to address drug shortages. It was founded by a group of U.S. health systems and philanthropies who, after more than a decade of chronic shortages, recognized that the market was not self-correcting and that a different approach is required. Civica works to deliver a safe, stable, and affordable supply of essential medicines to U.S. patients.   Media Contact: Liz Power liz.power@civicarx.org +1 860 501 3849 https://cbs4indy.com/business/press-releases/cision/20250807NY46213/governor-glenn-youngkin-announces-3-million-grant-to-support-civicas-affordable-insulin-programs/ XX If you or someone you love is living with diabetes, you already know the fight isn't just medical—it's financial, too. Between daily supplies, doctor visits, and long-term care, the cost of managing type 1 or type 2 diabetes can be overwhelming. Add college or trade school into the equation, and suddenly staying healthy competes with building a future. That's where scholarships for students with diabetes—like Beyond Scholars and others listed here—step in.   Whether you're headed to a university, a two-year college, or a hands-on trade program, these opportunities were created to ease the load.   Scholarships for students with diabetes Beyond Scholars (from Beyond Type 1): $10,000 for recently graduated high school seniors with type 1 diabetes or type 2 diabetes entering college or trade school. This is one of the largest needs-based diabetes scholarships in the United States. This year, awardees will also receive 6 months of wellness coaching through Risely Health.   Applications open: July 25, 2025 Deadline: August 29, 2025 Winners announced: October 2025 https://beyondtype1.org/beyond-scholars-diabetes-scholarships-college-trade-school/ XX Nick Jonas and Kyle Rudolph are using their platforms for a good cause.   On Tuesday, Aug. 12, the singer and the former NFL tight end (via his professional fundraising platform Alltroo) announced they're teaming up to launch a rally featuring a fan-coveted prize: a custom 2025 Volkswagen ID. Buzz electric bus that the Jonas Brothers have brought along for their 20th anniversary tour.   “Ten years ago, we hit the road with a goal to change what it means to live with diabetes. Since then, Beyond Type 1 has grown into the world's largest digital diabetes community, offering the tools, education, and peer support needed to not only survive but thrive with diabetes,” Jonas, who co-founded Beyond Type 1 (a nonprofit that advocates for those living with diabetes), says in a statement.     “We've challenged stigma, built community, provided life-saving resources, and collectively driven global innovation toward prevention and cure. This milestone is a moment to rally even more support for our mission, and partnering with Alltroo helps us do that in a powerful, engaging way.”   Related Stories Nick Jonas on Managing His Diabetes: 'The Mental and Emotional Health Aspect Is Really Important' nick jonas Nick Jonas Says He Was Diagnosed with Diabetes After Joe Told Their Parents: 'Something's Really Wrong' Joe Jonas and Nick Jonas attend the amfAR Cannes Gala 30th edition at Hotel du Cap-Eden-Roc on May 23, 2024 For Rudolph, the campaign is about "celebrating Beyond Type 1's incredible work over the past decade, and standing behind their vision of a world where everyone with diabetes — or at risk of it — has access to the knowledge, care and support needed for early diagnosis and lifelong health."   While the rally is live on Alltroo.com, fans can also scan QR codes available at all 36 Jonas Brothers concert stops to enter for a chance to win the electric bus. (A winner will be selected on November 14, which is World Diabetes Day.)   Jonas, 32, has long been open about his Type 1 diabetes diagnosis at 13 years old. "I had this kind of wrench thrown into things when I was diagnosed and it took a while to figure out how to count carbs to properly dose for insulin and what things would affect me in different ways," he previously told PEOPLE.   "When I was first diagnosed, I was sitting in the hospital and was scared to death, honestly, while I was learning about how to manage this new thing I was dealing with," Jonas recalled. "It would have been amazing to have someone to look at at that time to say, oh, this is a person living with it and they're following their dreams. They're doing what they want to do with their lives and not letting it slow them down."           https://people.com/nick-jonas-kyle-rudolph-launch-fan-rally-diabetes-awareness-11788684

While it’s been easy to grow a bit desensitized to the seemingly unstoppable sales growth of Novo Nordisk and Eli Lilly’s GLP-1s quarter after quarter, this most recent earnings season delivered a few surprises. It’s a good moment to jump back in and assess where the two rivals stand in the market and where their pipelines are headed in the near term. In this week’s episode of "The Top Line," we break down the recent commercial performances of Novo’s and Lilly’s drugs for diabetes and obesity, plus the status of their oral obesity med prospects. Fierce Biotech’s James Waldron sits down with Fierce Pharma’s Fraiser Kansteiner to discuss the latest in the companies’ ongoing obesity duel, as well as some recent pitfalls that seem common to GLP-1 development and commercialization more broadly. To learn more about the topics in this episode: Novo's outgoing CEO prepares to hand off business as sales threats from Lilly, GLP-1 compounders persist Amid MFN talks, Lilly chief warns US adoption of international drug prices could bring 'worst of two worlds' Novo Nordisk drops 2 obesity drugs as part of major pipeline clearout Lilly's oral GLP-1 data 'as good as it gets' at 12% weight loss, exec says Pfizer's embattled obesity program loses another GLP-1 over poor data and strong competition See omnystudio.com/listener for privacy information.

Kristina Partsinevelos opens with the market theme before Rick Santelli breaks down bond market reaction to the latest PPI. Steve Liesman explains what drove the number. Former Fed Governor Frederic Mishkin shares insight on the economy and the Fed's next steps.Earnings focus turns to Applied Materials, while our Leslie Picker covers 13F filings. Bob Elliott of Unlimited and Kristina Hooper of Man Group weigh in on market direction, and Chris Retzler of Needham highlights a big week for small caps. Angelica Peebles reports on Eli Lilly raising Mounjaro prices in Europe in response to Trump's pressure. 

As Alaska awaits the arrival tomorrow of the US and Russian Presidents, we're in Anchorage for a preview of their summit - and hear what one Ukrainian woman in the north-eastern city of Kharkiv expects from it.Also on the programme:Why has the pharmaceutical giant Eli Lilly decided to hike the price of the weight loss drug Mounjaro in the UK?Israel says it will push ahead with plans to build more settlements in the West Bank. We have Palestinian reaction.And the A-level student spending results day evening at her local pub - because she runs it. We speak to the UK's youngest pub landlady.

Cramer says he wants to buy back shares of this pharma giant. Become a CNBC Investing Club member to go behind the scenes with Jim Cramer and Jeff Marks as they talk candidly about the market's biggest headlines. Signup here: cnbc.com/morningtake CNBC Investing Club Disclaimer

In this episode, we talk with Dr. Christina Shenvi about ARIA, a finding associated with an early stage Alzheimer's infusion that can impact stroke and VTE care. The MRI of choice per neuroradiology are the T2 weighted and flare images seen on most routine head MRIs. The gradient recall echo are best for bleed and microhemorrhage. These are all part of a routine MRI. I would note in the order that you are looking for ARIA. Supported by Eli Lilly and Company

【欢迎订阅】 每天早上5:30，准时更新。 【阅读原文】 标题：Indian firms aim to gorge on weight-loss drugs Domestic demand is surging. And Indian generics could make slimming cheaper worldwide 正文：Until recently, Indians had few safe ways of joining the global craze for weight-loss drugs. Some smuggled them into the country when returning home from abroad; others chanced it with bootlegged versions from Dubai. But in March Mounjaro, a weight-loss drug from Eli Lilly, an American pharmaceutical giant, became legally available in India. In June Wegovy, a drug from Novo Nordisk, a Danish firm, followed. 知识点：craze /kreɪz/，n. an enthusiastic and widely shared passion for something, especially one that is short-lived.（狂热；时尚） • There was a craze for skateboarding among teenagers that year.那年青少年中掀起了一股滑板热。 获取外刊的完整原文以及精讲笔记，请关注微信公众号「早安英文」，回复“外刊”即可。更多有意思的英语干货等着你！ 【节目介绍】 《早安英文-每日外刊精读》，带你精读最新外刊，了解国际最热事件：分析语法结构，拆解长难句，最接地气的翻译，还有重点词汇讲解。 所有选题均来自于《经济学人》《纽约时报》《华尔街日报》《华盛顿邮报》《大西洋月刊》《科学杂志》《国家地理》等国际一线外刊。 【适合谁听】 1、关注时事热点新闻，想要学习最新最潮流英文表达的英文学习者 2、任何想通过地道英文提高听、说、读、写能力的英文学习者 3、想快速掌握表达，有出国学习和旅游计划的英语爱好者 4、参加各类英语考试的应试者（如大学英语四六级、托福雅思、考研等） 【你将获得】 1、超过1000篇外刊精读课程，拓展丰富语言表达和文化背景 2、逐词、逐句精确讲解，系统掌握英语词汇、听力、阅读和语法 3、每期内附学习笔记，包含全文注释、长难句解析、疑难语法点等，帮助扫除阅读障碍。

Two pharma giants, Eli Lilly and Novo Nordisk, are in a high-stakes race for leadership in the $150 billion GLP-1 obesity drug market. We examine Lilly's latest earnings, the mixed results from its oral pill orforglipron, and Novo's push with higher-dose oral semaglutide. We also look at how manufacturing scale, global expansion, and a growing compounding drug controversy could shape the outcome. This is the inside story of the GLP-1 wars and the companies vying to define the future of weight loss.This video is for informational purposes only and reflects the views of the host and guest, not Public Holdings or its subsidiaries. Mentions of assets are not recommendations. Investing involves risk, including loss. Past performance does not guarantee future results. For full disclosures, visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Public.com/disclosures⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.

In this week's episode of Dividend Talk, we kick off with our Q2 performance review , looking at how our dividend portfolios fared, what we bought, sold, and learned over the past quarter.  We also dive into three big names making headlines: Wolters Kluwer's sharp share price drop and the fear of AI disruption, Novo Nordisk's earnings and competition with Eli Lilly, and UnitedHealth's reduced outlook.  Along the way, we cover dividend hikes and cuts from around the globe, have some laughs over corporate slogans, and answer a packed list of listener questions ranging from sector risks to portfolio construction. SEE YOU ON THE INSIDE!! Tickers discussed: WKL.AS, NVO, LLY, UNH, HEIA.AS, NN.AS, AD.AS, ITW, CLX, AWR, WHR, LGEN.L, MRK, LVMH.PA, TGT, LYB, NKE,CVX, HPQ, MSFT, SHEL, BTI, BAM, BAES.L, HORNB.BR, UPS, PEP, CCOI, ORA.PA,ASR.AS, ASML.AS, UL, GLB.IR, KRZ.F, KESKOB.HE, KNEBV.HE, SAMPO.HE, AGE.BR, XIOR.BR,ASC.BR, SHL.DE, DEF.F, NVO-B.CO, VICI, RY, DOL.TO, FTS.TO, UKW.L, VOLVB.ST,INVE-A.ST, INVE-B.ST, SEB-A.ST, SWED-A.ST, HAND-B.ST, SHELL.AS, VIE.PA, O,SECUB.ST, ABBV, BAYN.DE.  Join us :[Facebook]  - Https://www.facebook.com/groups/dividendtalk[Twitter] -   @DividendTalk_    ,  @European_DG[Discord] - https://discord.gg/nJyt9KWAB5[Premium Services] - https://dividendtalk.eu/how-it-works

Ozempic, a medication originally designed to treat type two diabetes, remains at the center of public fascination and debate due to its widespread use for weight loss. In just the last week, new research and celebrity commentary have deepened the conversation about both the benefits and potential drawbacks of this so-called game-changing drug. A study published by University of Utah Health early this week explored how Ozempic-induced weight loss affects a person's body composition. According to the study, while individuals can lose a significant portion of their overall weight on Ozempic, the reduction in muscle mass may not be as severe as previously thought. Most of the decrease in lean mass in test subjects was traced to non-muscle tissues, particularly the liver, which actually shrank by about half its original size in the animal model. The loss of liver mass may be a healthy component of weight loss, potentially reducing the risk of conditions like fatty liver disease. However, the researchers also observed that some skeletal muscles experienced as much as a six percent decrease in size and, most notably, these muscles could become weaker even if their actual volume did not change much. This raises pressing questions about how using Ozempic for significant weight loss could impact strength and mobility. The senior author of the study, Katsu Funai, highlighted the urgent need for robust human-based research to clarify the actual risk and benefit profile of Ozempic among real-world users, especially as its popularity continues to spread.Media coverage over the past few days has turned a spotlight on “Ozempic feet,” a term being used to describe visible changes to the feet resulting from rapid weight loss on the medication. According to experts quoted in a recent AOL report, several celebrities, including Oprah Winfrey and Sharon Osbourne, have reportedly experienced such side effects. As fat and even some muscle mass are shed, the skin on the feet can become saggy and wrinkled and the fit of shoes is often altered, sometimes leading to pain or discomfort. Though some of these changes are a natural consequence of losing substantial weight, experts caution that adjustments, including choosing new footwear or orthotic inserts, may be necessary for comfort and stability.The conversation took a more personal and reflective turn this week as Oprah Winfrey publicly discussed her own history with weight loss and the use of Ozempic. During a live WeightWatchers event, Oprah issued a heartfelt apology for having sparked unhealthy diet culture over the years through her previous messaging on her talk show and in her magazines. This apology comes after she acknowledged earlier this year that she herself lost forty pounds using a weight-loss medication understood to be Ozempic, despite having previously referred to the use of such drugs as “the easy way out.” Her frank disclosure adds a human dimension to the ongoing debate, underscoring the complexity of weight, self-image, and the tools available for managing health.Despite the buzz, it is important for listeners to know that not all effects of Ozempic are positive or enduring. Semaglutide, the main ingredient in Ozempic, has been linked in recent studies to significant muscle loss, particularly in women and older adults. Research published this week warns that when people stop taking Ozempic or similar GLP-1 receptor agonist drugs, they frequently experience a rebound effect, regaining a substantial portion of the weight lost during treatment. The extent of this weight regain varies but tends to occur consistently within weeks of discontinuation. Experts say that the magnitude of this rebound likely depends on the drug and the user's commitment to lifestyle changes during and after medication.As pharmaceutical companies race to develop new and potentially better alternatives, Eli Lilly recently unveiled that its oral weight-loss drug, orforglipron, could achieve double-digit percent reductions in body weight and offer a pill-based alternative to injectables like Ozempic. However, as with all medications, these advancements will need rigorous study to understand their long-term impact on health, including muscle and organ integrity.Thanks for listening, please subscribe, and remember—this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai. Be sure to come back next week for more.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.ai

Today's Headlines: We're ending the week on a truly chaotic note. Texas Senator John Cornyn got the FBI involved to help track down state Democrats who fled to avoid a rushed redistricting vote—one that would give Republicans five extra seats, just because Trump said they should have them. Trump's also pushing for early redistricting in other red states and floated a new census that would exclude undocumented immigrants—never mind what the Constitution says. In other news, he signed an order demanding colleges hand over race-based admissions data, and the Air Force is cutting off early retirement benefits for transgender service members. Additionally, Trump now wants your 401(k) to dabble in crypto and real estate, and he's nominating an aide to the Fed who's big on lowering interest rates. Finally, Apple CEO Tim Cook gave Trump a weird gold iPhone trophy, VP JD Vance's river was allegedly raised for his birthday kayak trip, Israel confirmed it plans to take full control of Gaza, and Eli Lilly released promising results from a study of its new weight loss pill. Resources/Articles mentioned in this episode: NBC News: Sen. John Cornyn says the FBI granted his request to help find absent Texas Democrats WaPo: Led by Trump, Republicans push to redraw election maps in multiple states Axios: Trump says he's ordering a new census. Here's what the Constitution says Axios: Trump orders colleges to report race data AP News: Trump's Air Force denies retirement pay to ex-trans service members Axios: Trump to supercharge private equity with 401(k) order PBS: Trump says he is nominating top economic aide Stephen Miran to Federal Reserve board The Verge: Apple made a 24k gold and glass statue for Donald Trump AP News: JD Vance went kayaking for his birthday. Secret Service had the river level raised AP News: Netanyahu says Israel plans to take over Gaza to destroy Hamas Wired: Eli Lilly's Obesity Pill Shows Promising Weight Loss in New Results Morning Announcements is produced by Sami Sage and edited by Grace Hernandez-Johnson Learn more about your ad choices. Visit megaphone.fm/adchoices

See omnystudio.com/listener for privacy information.

Nicole Murray joins the show to discuss a wide range of timely topics. Markets saw mixed movement, with the Dow down and the NASDAQ and S&P 500 on the rise. She covers Schnucks' new 68,000 sq. ft. store coming to Creve Coeur, OpenAI's release of ChatGPT-5, and Eli Lilly's groundbreaking weight-loss pill. Other highlights include a drop in mortgage rates, a troubling rise in imposter scams targeting seniors, and a conversation on the trending “FAFO” parenting approach.

S&P Futures are displaying positive action this morning as the Trump tariffs went into effect overnight. Trade talks with other countries continue. The White House agreed to cease the stacking of tariffs on Japan. The China agreement is set to expire next week. India is said to be open to reducing oil imports from Russia as part of a tariff settlement. Late yesterday, President Trump nominated Stephen Miran, the current chair of the White House Council of Economic Advisers, to fill a temporary vacancy on the Federal Reserve's Board of Governors. The anticipation of a Trump Putin meeting to end the conflict in Ukraine continues to have a positive effect on markets sentiment. Antitrust officials in the U.K. effectively cleared Boeing's plan to acquire Spirit AeroSystems Holdings. Eli Lilly's weight-loss pill produced underwhelming results. Economic calendar is light today; the next key report is the CPI data that is due out on Tuesday. EXPE, CART, MNST, TTWO & GILD are higher after earnings releases, TTD, TWLO, MCHP, FLUT & GDDY are lower. On Monday morning, earnings reports are expected from RUM, LEGN, ROIV, MNDY & B

U.S. Homeland Security Secretary Kristi Noem thanked Indiana Governor Mike Braun for expanding detention beds and dubbed the added space the “Speedway slammer.”  A series of lawsuits have been filed in Marion County court against drug manufacturer Eli Lilly. Republicans from the Indianapolis City-County Council are proposing new ideas to combat youth violence.  Indianapolis announced Wednesday it replaced and upgraded HVAC systems at a senior living center, using federal funds meant to improve energy efficiency. Vice President JD Vance met with Governor Mike Braun Thursday to discuss redrawing Indiana's congressional district lines to benefit Republicans. Want to go deeper on the stories you hear on WFYI News Now? Visit wfyi.org/news and follow us on social media to get comprehensive analysis and local news daily. Subscribe to WFYI News Now wherever you get your podcasts. WFYI News Now is produced by Drew Daudelin, Zach Bundy and Abriana Herron, with support from News Director Sarah Neal-Estes.

Get My Book On Amazon: https://a.co/d/avbaV48Download The Peptide Cheat Sheet: https://peptidecheatsheet.carrd.co/Download The Bioregulator Cheat Sheet: https://bioregulatorcheatsheet.carrd.co/

Endnu en vild uge på aktiemarkederne lakker mod enden. Millionærklubben samler op på ugens store begivenheder, hvor særligt Novo Nordisk og ærkerivalen Eli Lilly har stjålet rampelyset. Med i studiet er teknisk analytiker Lars Persson og chefanalytiker i Svenssen og Tudborg, Lau Svenssen, der sætter ord på de store kursbevægelser, tjekker ind på markedet i dag, og svarer på spørgsmål fra lytterne. Vært: Laura Bitte RossauSee omnystudio.com/listener for privacy information.

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Nando Sommerfeldt über das Wettrennen um die Fed-Spitze, einen ungewohnten Rheinmetall-Rücksetzer und starke Siemens-Zahlen. Außerdem geht es um Intel, Amgen, Merck, Abbvie, Pfizer, Eli Lilly, Novo Nordisk, Pinterest, Rheinmetall, Deutsche Telekom, Siemens, Allianz, Ionos, Microsoft, Alphabet, Softbank und AirBnB. Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Eli Lilly is facing significant drug pricing pressure, with issues ranging from the pricing of their weight loss pill Orfoglipron to market battles with competitors like Novo Nordisk. Despite the challenges, Lilly's executives see opportunities for their products in the real world. Jazz Pharmaceuticals received FDA approval for Dordaviprone, making it the first new treatment for an ultra-rare brain tumor. In other news, Sarepta beat Q2 estimates despite not holding an investor call, and Trilink Biotechnologies is offering process development services for nucleic acid therapeutic development. Lotte Biologics is expanding its global CDMO operations, while a big pharma-backed mRNA startup raised $153 million in funding. Novo Nordisk's new CEO is focusing on obesity and diabetes, Pfizer is in talks with Trump on most favored nation drug pricing, and Bayer expects more layoffs. These developments in the pharma and biotech world showcase the ongoing challenges and opportunities in the industry. Stay tuned for more updates on the latest news and trends in this rapidly evolving sector.

Aktien hören ist gut. Aktien kaufen ist besser. Bei unserem Partner Scalable Capital geht's unbegrenzt per Trading-Flatrate oder regelmäßig per Sparplan. Alle weiteren Infos gibt's hier: scalable.capital/oaws. Aktien + Whatsapp = Hier anmelden. Lieber als Newsletter? Geht auch. Das Buch zum Podcast? Jetzt lesen. Siemens und Allianz performen. Telekom und Rheinmetall nicht ganz. Tschechien kriegt bald krasse Rüstungs-Aktie. Firefly ist krasse Space-Aktie. Eli Lilly leidet unter Pille. Trump will Intel-CEO feuern. Celsius, Dutch Bros und Duolingo = stark. Crocs & Fortinet = schwach. Scout24 (WKN: A12DM8) bald im DAX? Wie steht's um die Gig Economy? Die ersten werden die letzten sein = Airbnb (WKN: A2QG35). Uber-Flieger (WKN: A2PHHG) gibt es noch und DoorDash (WKN: A2QHEA) hat keinen Wachstums-Crash. Diesen Podcast vom 08.08.2025, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

Inside INdiana Business Radio for the morning of August 8, 2025. Eli Lilly shares drop more than 14% despite second-quarter revenue of $15.6 billion, as analysts react to trial data on a weight loss pill. Purdue University Airport opens its $12 million Amelia Earhart terminal with new flights to Chicago. Also: Ivy Tech partners with a Swiss firm on cybersecurity training, Vincennes hosts the Cal Ripken World Series, and IU names a new Public Policy Institute director. Get the latest business news from throughout the state at InsideINdianaBusiness.com.

Apple seeing another day of gains, as investors pile in after CEO Tim Cook's appearance in the oval office. How the tech giants U.S. investment is putting it in President Trump's good graces, and if the stock's climb will continue. Plus Shares of Eli Lilly plummeting after the pharma giant posted disappointing results for its weight loss pill. What one top health care analyst sees in store for the stock, and the next move in the weight loss drug race. Fast Money Disclaimer

U.S.tariffs kicked in on imports from dozens of countries just after midnight. Plus: Apple announces an extra $100 billion commitment to U.S. manufacturing. Eli Lilly's weight-loss pill showed less than expected results. And, Crocs warns of a quarterly sales decline and an annual hit from tariffs. Charlotte Gartenberg hosts. Sign up for the WSJ's free What's News newsletter. An artificial-intelligence tool assisted in the making of this episode by creating summaries that were based on Wall Street Journal reporting and reviewed and adapted by an editor. Learn more about your ad choices. Visit megaphone.fm/adchoices

President Trump has announced he will impose a 100% tariff on chips and semiconductors imports, although he's suggested exemptions for companies manufacturing in the U.S. One company that may qualify for that exemption: Apple. During CEO Tim Cook's meeting with the President on Wednesday, Cook committed an additional $100 billion to onshore manufacturing. Author Walter Isaacson discusses Cook's commitment in the context of Steve Jobs' original plans to manufacture Apple products in America. President Trump also has another tech CEO in his sights, calling for the resignation of Intel's Lip-Bu Tan on social media. CNBC's Angelica Peebles reveals the latest obesity pill trial results from Eli Lilly. Orfoglipron's results were similar to Wegovy, and investors are disappointed by the data and the rate of discontinuation among trial participants. Plus, Lyft CEO David Risher explains his company's earnings report, strong on paper but disappointing to some investors.  Megan Cassella - 5:35Angelica Peebles - 13:03Walter Isaacson - 20:47David Risher - 35:21 In this episode:Megan Cassella, @mmcassellaAngelica Peebles, @angelicapeeblesJoe Kernen, @JoeSquawk Andrew Ross Sorkin, @andrewrsorkinMelissa Lee, @MelissaLeeCNBCKatie Kramer, @Kramer_Katie

Cramer reacts to this pharma giant's drug trial that failed to impress. Become a CNBC Investing Club member to go behind the scenes with Jim Cramer and Jeff Marks as they talk candidly about the market's biggest headlines. Signup here: cnbc.com/morningtake CNBC Investing Club Disclaimer

Carl Quintanilla, David Faber, and Leslie Picker began the hour by breaking down the President's new claim that he would impose a 100% tariff on imports of semiconductors and chips, but not for companies that are “building in the United States.” Separately, he also called out Intel and said the CEO should resign immediately after saying Lip-Bu Tan is “highly conflicted” following reports to his potential ties to Chinese companies. CNBC's Angelica Peebles also joined the program to discuss Eli Lilly shares plunging following some disappointing weight loss data. Also in the mix; ConocoPhillips CEO exclusively broke down his company's latest results.  Squawk on the Street Disclaimer

Carl Quintanilla, Jim Cramer and David Faber discussed developments involving the White House and the tech sector: President Trump announced 100% percent tariffs on semiconductor imports, with exemptions for chipmakers who invest in the United States. Taiwan Semiconductor among the chip companies rallying on that news. Apple shares extended their gains one day after the president and Tim Cook met at the White House to announce Apple expanding its commitment to investing in the U.S. In a Truth Social post, Trump called on Intel CEO Lip-Bu Tan to resign. Eli Lilly shares tumbled as weight-loss pill trial results overshadowed an earnings beat and raised guidance. Also in focus: DoorDash among the earnings winners, Paramount and Skydance complete their merger.Squawk on the Street Disclaimer

A new wave of tariffs takes effect — what it means for global markets and American consumers. Also, United Airlines flights resume after the airline resolves a technology issue that caused ground stops at several major U.S. airports. Plus, Eli Lilly says it's one step closer to FDA approval for a first-of-its-kind oral weight loss medication. And, what to do about cruise fare hikes and where to find the best deals on sea travel.

Tara Hastings sound board updated. Don't screw with the Speedway 8:16: US Soldier charged with espionage. Trump calling for a new census, Eli Lilly boosts outlook, Tony's Mayim Bialik True Hollywood StorySee omnystudio.com/listener for privacy information.

FIVE soldiers shot at Fort Stewart in Georgia, United Airlines outage, Bill Hemmer reports he saw a lot of healthy people in Gaza, Mahmoud Khalil: "We" couldn't avoid carrying out the October 7th massacre because Israel was making peace with the Saudis, and the Palestinians felt left out, Tony's Yacht Rock experience last night, Until Deepfake video is proven to exist, the allegations are just allegations, Stellantis layoffs. Bolton: Putin believes that he can work Trump at Summit being planned. Free Raggedy Butt Couch. JD Vance denies secret meeting with Bondi to discuss "Epstein Strategy", Tara Hastings sound board updated. Don't screw with the Speedway 8:16: US Soldier charged with espionage. Trump calling for a new census, Eli Lilly boosts outlook, Tony's Mayim Bialik True Hollywood StorySee omnystudio.com/listener for privacy information.

A new study says ChatGPT told researchers posing as teenagers how to get alcohol and drugs, suggested ways to hide eating disorders and more after initially providing warnings. The researchers were pretending to be 13 years old. CBS News senior business and technology correspondent Jo Ling Kent explains. As Sean "Diddy" Combs awaits his sentencing, his lead attorney Marc Agnifilo says he has not talked to anyone at the White House about a possible pardon. Agnifilo sat down with CBS News' Jericka Duncan in his first network interview since the highly publicized trial. A first-of-its-kind pill from Eli Lilly that addresses weight loss and diabetes is showing signs of success at its clinical trial. CBS News medical contributor Dr. Celine Gounder breaks down what to know. Jenny Han, the creator and showrunner of the hit series "The Summer I Turned Pretty," joins "CBS Mornings" to talk about the final season of the show and fan theories about how it could end. The popular show is a coming-of-age story about Belly, who finds herself caught in a love triangle between two brothers. Singer-songwriter Charles Kelley, a member of the band Lady A, talks about exploring a new sound with his second solo album, his sobriety journey and fatherhood. Actors Seth Rogen and Rose Byrne talk about their return for a new season of the comedy series "Platonic." They play Will and Sylvia, college best friends trying to maintain their close friendship as they navigate adulthood and personal relationships. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

How can low beta stocks help savvy investors sidestep the pain of the Dot-Com Bust? Lance Roberts & Michael Lebowitz reveal why that lesson matters today...what low beta investing means, how it works in bear markets, and how it can protect your portfolio from bubbles and volatility. Lance reviews market reaction to tariffs coming completely online, and Apple's commitment to re-shore manufacturing to the US; the multiplier effect of domestic manufacturing. A look at Eli Lilly's successful completion of trials for its GLP pill; markets continue to hover along the 20-DMA. Lance and Michael discuss the AI phenomenon; what it really means when we're talking about "the market;" what is the cycle that is sustaining the stock market? How will younger investors' habits imprint market dynamics. What will trigger a crisis of confidence in the market; Lance and Michael discuss the importance of continuous risk management. SEG-1: Tariffs Are Fully in Effect - Market Response SEG-2a: Markets Continue to Defy Dire News SEG-2b: Is the AI Bubble the Same as the Dot-com Bubble? SEG-2c: Commentary on the Concentration on AI Stocks SEG-2d: What Do We Mean when We Say, "Market?" SEG-2e: The Virtuous Cycle Lifting Markets Higher SEG-2f: Impact & Influence of Younger Investors' Habits SEG-2g: What Will Be the Crisis of Confidence? SSEG-2h: The Importance of Risk Management Hosted by RIA Advisors RIA Chief Investment Strategist, Lance Roberts, CIO, w Portfolio Manger, Michael Lebowitz, CFA Produced by Brent Clanton, Executive Producer ------- Watch today's video on YouTube: https://www.youtube.com/watch?v=xW8-B15zzCk&list=PLVT8LcWPeAugpcGzM8hHyEP11lE87RYPe&index=1&t=3s ------- The latest installment of our new feature, Before the Bell, "8-7-25 Is the Correction Over?" is here: https://www.youtube.com/watch?v=UEX8Ev1PJgo&list=PLwNgo56zE4RAbkqxgdj-8GOvjZTp9_Zlz&index=1 ------- Our previous show is here: "How to Build a Winning Investment Portfolio | What to Buy & What to Avoid in 2025 " https://www.youtube.com/watch?v=OYKQ9V4PIfU&list=PLVT8LcWPeAugpcGzM8hHyEP11lE87RYPe&index=1 ------- Register for our next Candid Coffee, "Savvy Social Security Planning," August 23, 2025: https://streamyard.com/watch/pbx9RwqV8cjF ------- Get more info & commentary: https://realinvestmentadvice.com/newsletter/ -------- SUBSCRIBE to The Real Investment Show here: http://www.youtube.com/c/TheRealInvestmentShow -------- Visit our Site: https://www.realinvestmentadvice.com Contact Us: 1-855-RIA-PLAN -------- Subscribe to SimpleVisor: https://www.simplevisor.com/register-new -------- Connect with us on social: https://twitter.com/RealInvAdvice https://twitter.com/LanceRoberts https://www.facebook.com/RealInvestmentAdvice/ https://www.linkedin.com/in/realinvestmentadvice/ #TechnicalAnalysis #MarketRisk #MarketCorrection #MarketRally #20DMA #LowBetaStocks #DotComBubble #RiskManagement #StockMarketCrash #DefensiveInvesting#InvestingAdvice #Money #Investing

VISIT ALL OUR LINKS: https://linktr.ee/manonthemounjaro

How can low beta stocks help savvy investors sidestep the pain of the Dot-Com Bust? Lance Roberts & Michael Lebowitz reveal why that lesson matters today...what low beta investing means, how it works in bear markets, and how it can protect your portfolio from bubbles and volatility. Lance reviews market reaction to tariffs coming completely online, and Apple's commitment to re-shore manufacturing to the US; the multiplier effect of domestic manufacturing. A look at Eli Lilly's successful completion of trials for its GLP pill; markets continue to hover along the 20-DMA. Lance and Michael discuss the AI phenomenon; what it really means when we're talking about "the market;" what is the cycle that is sustaining the stock market? How will younger investors' habits imprint market dynamics. What will trigger a crisis of confidence in the market; Lance and Michael discuss the importance of continuous risk management. SEG-1: Tariffs Are Fully in Effect - Market Response  SEG-2a: Markets Continue to Defy Dire News SEG-2b: Is the AI Bubble the Same as the Dot-com Bubble? SEG-2c: Commentary on the Concentration on AI Stocks SEG-2d: What Do We Mean when We Say, "Market?" SEG-2e: The Virtuous Cycle Lifting Markets Higher SEG-2f: Impact  & Influence of Younger Investors' Habits SEG-2g: What Will Be the Crisis of Confidence? SSEG-2h: The Importance of Risk Management Hosted by RIA Advisors RIA Chief Investment Strategist, Lance Roberts, CIO, w Portfolio Manger, Michael Lebowitz, CFA Produced by Brent Clanton, Executive Producer ------- Watch today's video on YouTube: https://www.youtube.com/watch?v=xW8-B15zzCk&list=PLVT8LcWPeAugpcGzM8hHyEP11lE87RYPe&index=1&t=3s ------- The latest installment of our new feature, Before the Bell, "8-7-25 Is the Correction Over?" is here:  https://www.youtube.com/watch?v=UEX8Ev1PJgo&list=PLwNgo56zE4RAbkqxgdj-8GOvjZTp9_Zlz&index=1 ------- Our previous show is here: "How to Build a Winning Investment Portfolio | What to Buy & What to Avoid in 2025 " https://www.youtube.com/watch?v=OYKQ9V4PIfU&list=PLVT8LcWPeAugpcGzM8hHyEP11lE87RYPe&index=1 ------- Register for our next Candid Coffee, "Savvy Social Security Planning," August 23, 2025: https://streamyard.com/watch/pbx9RwqV8cjF ------- Get more info & commentary:  https://realinvestmentadvice.com/newsletter/ -------- SUBSCRIBE to The Real Investment Show here: http://www.youtube.com/c/TheRealInvestmentShow -------- Visit our Site: https://www.realinvestmentadvice.com Contact Us: 1-855-RIA-PLAN -------- Subscribe to SimpleVisor: https://www.simplevisor.com/register-new -------- Connect with us on social: https://twitter.com/RealInvAdvice https://twitter.com/LanceRoberts https://www.facebook.com/RealInvestmentAdvice/ https://www.linkedin.com/in/realinvestmentadvice/ #TechnicalAnalysis #MarketRisk #MarketCorrection #MarketRally #20DMA #LowBetaStocks #DotComBubble #RiskManagement #StockMarketCrash #DefensiveInvesting#InvestingAdvice #Money #Investing

Treasury auctions could help set direction for yields and stocks, and tariffs hit imports from dozens of countries. Eli Lilly is a major earnings report to watch this morning.Important DisclosuresThis material is intended for general informational purposes only. This should not be considered an individualized recommendation or personalized investment advice. The investment strategies mentioned may not be suitable for everyone. Each investor needs to review an investment strategy for his or her own particular situation before making any investment decisions.The Schwab Center for Financial Research is a division of Charles Schwab & Co., Inc.All names and market data shown above are for illustrative purposes only and are not a recommendation, offer to sell, or a solicitation of an offer to buy any security. Supporting documentation for any claims or statistical information is available upon request.Past performance is no guarantee of future results.Diversification and rebalancing strategies do not ensure a profit and do not protect against losses in declining markets.Indexes are unmanaged, do not incur management fees, costs, and expenses and cannot be invested in directly. For more information on indexes, please see schwab.com/indexdefinitions.The policy analysis provided by the Charles Schwab & Co., Inc., does not constitute and should not be interpreted as an endorsement of any political party.Fixed income securities are subject to increased loss of principal during periods of rising interest rates. Fixed income investments are subject to various other risks including changes in credit quality, market valuations, liquidity, prepayments, early redemption, corporate events, tax ramifications, and other factors.All expressions of opinion are subject to change without notice in reaction to shifting market, economic or political conditions. Data contained herein from third party providers is obtained from what are considered reliable sources. However, its accuracy, completeness or reliability cannot be guaranteed.Investing involves risk, including loss of principal, and for some products and strategies, loss of more than your initial investment.The Schwab Center for Financial Research is a division of Charles Schwab & Co., Inc.Apple Podcasts and the Apple logo are trademarks of Apple Inc., registered in the U.S. and other countries.Google Podcasts and the Google Podcasts logo are trademarks of Google LLC.Spotify and the Spotify logo are registered trademarks of Spotify AB.(0131-0825)

Eli Lilly's (LLY) earnings beat wasn't enough draw investors in. The bigger focus was on the company's weight loss pill that showed "disappointing" results. Jenny Horne talks about why the results weighed so heavy on Eli Lilly's report. As for Airbnb (ABNB), company management warned of revenue softness over travel woes. Jenny compares the earnings to peers in the hotel space.======== Schwab Network ========Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/ About Schwab Network - https://schwabnetwork.com/about

"This market is priced for perfection," says Rebecca Walser, and it caused investors to see any red mark on Eli Lilly's (LLY) earnings as bearish. The stock plunged when its oral weight loss drug disappointed, though she believes there's more than enough market share for it to rebound. Andrew Wang agrees, adding that backing from the Trump administration "keeps me optimistic" on Eli Lilly's outlook. ======== Schwab Network ========Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/ About Schwab Network - https://schwabnetwork.com/about

This Day in Legal History: Gulf of Tonkin ResolutionOn August 7, 1964, the U.S. Congress passed the Gulf of Tonkin Resolution, dramatically reshaping the legal landscape of American military engagement. Prompted by reports—later disputed—of North Vietnamese attacks on the USS Maddox in the Gulf of Tonkin, the resolution granted President Lyndon B. Johnson broad authority to use military force in Southeast Asia without a formal declaration of war. It passed nearly unanimously, with only two dissenting votes in the Senate, reflecting the tense Cold War atmosphere and congressional trust in the executive branch.Legally, the resolution functioned as an open-ended authorization for the president to escalate military operations in Vietnam. Within months, it led to the deployment of hundreds of thousands of U.S. troops. Critics would later argue that it allowed the executive to bypass Congress's constitutional war-making powers, effectively green-lighting a years-long conflict based on contested facts.As the war dragged on and public opinion turned, the resolution became a focal point for debates over separation of powers, congressional oversight, and executive overreach. In 1971, amid growing backlash, Congress repealed the resolution, but its legacy endured. It served as a legal and historical precedent for future authorizations of force, including those passed after 9/11.A federal appeals court has upheld the SEC's long-standing “gag rule,” which prevents defendants who settle civil enforcement cases from publicly denying the agency's allegations. The 9th Circuit Court of Appeals ruled 3-0 that the rule is not unconstitutional on its face but left room for future challenges depending on how it's applied. The policy, in place since 1972, requires settling parties to at least refrain from admitting or denying wrongdoing. The court emphasized that defendants remain free to reject settlements if they wish to speak out.Twelve petitioners, including former Xerox CFO Barry Romeril and the New Civil Liberties Alliance (NCLA), challenged the SEC's January 2024 decision not to revise the rule. Romeril had previously brought a similar challenge to the Supreme Court with support from Elon Musk, but the Court declined to hear it. Writing for the panel, Judge Daniel Bress noted that removing the gag could reduce the SEC's ability to settle cases efficiently and that speech restrictions are voluntary components of settlement agreements.The NCLA criticized the decision, arguing it effectively sanctions government-imposed silence and announced plans to pursue further appeals. SEC Commissioner Hester Peirce also dissented from the agency's refusal to revisit the rule, arguing that it hinders public accountability by suppressing potential criticism. The SEC declined to comment on the ruling, which came in the case Powell et al v. SEC.US appeals court upholds SEC 'gag rule' over free speech objections | ReutersThe Stanford Daily, Stanford University's student newspaper, has filed a lawsuit against the Trump administration, accusing it of violating the free speech rights of foreign students. The suit, filed in federal court in California, alleges that threats of arrest, detention, or deportation have created a climate of fear among international students, discouraging them from writing about sensitive political issues—particularly the Israeli-Palestinian conflict. Two unnamed students joined the paper in the lawsuit, which names Secretary of State Marco Rubio and Secretary of Homeland Security Kristi Noem as defendants.According to the plaintiffs, the administration has labeled pro-Palestinian viewpoints as antisemitic or extremist and attempted to deport students expressing such views, framing them as threats to U.S. foreign policy. In some instances, students have been detained without charges, though judges have later ordered their release. The lawsuit contends that these actions have led to widespread self-censorship among international students, chilling constitutionally protected speech in areas such as protests, slogans, and commentary on U.S. and Israeli policy.The Stanford Daily is seeking a court ruling affirming that the First Amendment protects non-citizens from government retaliation based on their speech. The university clarified it is not involved in the suit, as the newspaper operates independently. Attorney Conor Fitzpatrick, representing the paper, called the government's actions antithetical to American values of free expression.Stanford student newspaper sues Trump administration for alleged free speech violations | ReutersA U.S. appeals court has reinstated a lawsuit accusing major drugmakers Sanofi, Eli Lilly, Novo Nordisk, and AstraZeneca of conspiring to limit drug discounts provided under the federal 340B program. The 2nd Circuit Court of Appeals reversed a lower court's dismissal, allowing two health clinics—Mosaic Health and Central Virginia Health Services—to proceed with their proposed class action. These clinics claim the companies colluded in 2020 to restrict discounts on diabetes medications, harming safety-net providers and the low-income patients they serve.The court found that because the four companies control much of the diabetes drug market, coordination to limit discounts could be feasible. Judge Myrna Pérez, writing for the panel, noted the allegations were plausible enough to move forward. The drugmakers have denied wrongdoing and argue their policies were developed independently to address alleged fraud in the 340B program. Sanofi and Novo Nordisk said they are reviewing the decision, while Lilly criticized the ruling and defended its practices as legal.The clinics say the drugmakers earned billions in extra profits through these policies, which allegedly undercut essential savings for providers. The case underscores the broader tension between pharmaceutical companies and healthcare providers over the administration of the 340B program, which requires drugmakers to offer discounts in exchange for access to federal healthcare funds.US appeals court reinstates drug-price conspiracy lawsuit against Sanofi, rival pharma companies | ReutersPepsiCo is facing a proposed class action lawsuit alleging it engaged in illegal price discrimination by giving more favorable pricing and discount terms to large retailers like Walmart while denying the same deals to smaller businesses. Filed in federal court in Manhattan by an Italian restaurant operator, the lawsuit claims this practice violates the Robinson-Patman Act, a rarely enforced 1936 antitrust law meant to prevent discriminatory pricing that harms competition.The suit accuses Pepsi of providing payments and allowances to Walmart that were not extended to other retailers, placing smaller businesses at a competitive disadvantage. Although Walmart is named in the allegations, it is not a defendant in the case. The plaintiff argues that Pepsi's pricing tactics unfairly burden other merchants who must pay more for the same products.This legal action echoes a previous Federal Trade Commission (FTC) lawsuit filed against Pepsi in January under the Biden administration. However, the second Trump administration dropped the case in May, with Trump-appointed FTC Chair Andrew Ferguson criticizing it as a politically motivated effort launched too late in the prior administration's term. The FTC has not commented on the new private lawsuit.The class action seeks unspecified damages on behalf of thousands of Pepsi purchasers nationwide. Neither Pepsi nor Walmart has publicly responded to the allegations.Pepsi accused of price discrimination in new merchant class action | Reuters This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe

Stock market update for August 7, 2025. This video is for informational purposes only and reflects the views of the host and guest, not Public Holdings or its subsidiaries. Mentions of assets are not recommendations. Investing involves risk, including loss. Past performance does not guarantee future results. For full disclosures, visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Public.com/disclosures⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.

En el episodio de hoy de VG Daily, Eugenio Garibay y Andre Dos Santos recorren un torbellino de titulares que va de la Casa Blanca a Wall Street. Arrancan con la visita de Tim Cook a Donald Trump en donde Apple promete invertir millones adicionales en EE. UU. y, casi en la misma hora, la Administración impone aranceles del 100 % a chips fabricados fuera del país, disparando a Intel y TSMC mientras reconfigura las cadenas de suministro. El dúo enlaza ese golpe industrial con la nueva orden ejecutiva que autoriza incluir bitcoin, capital privado e inmobiliario en los planes 401(k), abriendo un cofre de casi US$ 9 billones al riesgo alternativo y encendiendo el debate fiduciario.En la arena corporativa, analizan los resultados de Eli Lilly que baten el consenso pero también el tropiezo bursátil provocado por los tibios datos de su píldora oral contra la obesidad. Un episodio que entrelaza política industrial, revolución del retiro y la pujante economía del bienestar, ofreciendo al oyente una panorámica completa de los motores que mueven el mercado esta semana.

The President calls for the resignation of the Intel CEO over alleged conflicts with China. Then Intel not the only company drawing the attention of the President. A look at Tim Cook the politician. How the Apple CEO is rewriting the playbook when it comes to getting around tariffs. And then Eli Lilly shares tank after data from a late-stage trial for its oral weight-loss drug overshadowed the company's upbeat outlook.

US President Trump said they are going to be putting a very large tariff on chips and semiconductors, which will be at approximately 100%, but added "if you're building in the US, there will be no charge."Crude futures declined yesterday amid Russia/Ukraine optimism following the discussion between the US and Russia which was said to have made progress and with President Trump intending to meet Russian President Putin as soon as next week.US President Trump said, regarding the Fed pick, that the interview process has started and it is probably down to three candidates, while he added that the two Kevins are very good, and a temporary governor is to be named in the next few days.APAC stocks traded mixed as reciprocal tariffs took effect overnight; European equity futures indicate a marginally higher cash market open with Euro Stoxx 50 futures up 0.4% after the cash market closed with gains of 0.3% on Wednesday.Looking ahead, highlights include German Trade (Jun), Industrial Output (Jun), Swedish CPIF (Jul), French Trade Balance (Jun), US Jobless Claims, Wholesale Sales (Jun) NY Fed SCE, Atalanta Fed GDP, BoE Announcement, MPR & DMP, CNB & Banxico Announcements, Speakers including BoE's Bailey & Fed's Bostic, Supply from Spain, France & US.Earnings from Trade Desk, Eli Lilly, ConocoPhillips, Vistra Energy, Peloton, Warner Bros, DataDog, Kenvue, Siemens, Deutsche Telekom, Allianz, Merck, Henkel, Rheinmetall, Deliveroo, Serco, Maersk, Zurich Insurance & WPP.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

Class-wide label change for opioids; positive results for oral GLP-1; migraine prevention therapy approved for children; FDA removes restriction on Ixchiq for older adults; Modeyso approved for rare brain tumor.

Inside INdiana Business Radio for the afternoon of August 7, 2025. Greenfield-based Elanco Animal Health is expanding the use of its medication for canine parvovirus after receiving approval to use the drug for preventative treatment. Eli Lilly and Co. stock fell Thursday amid "disappointing" results from clinical trials for its weight-loss pill. Plus, Franciscan Health hits a construction milestone for its new cancer center in Crown Point. Get the latest business news from throughout the state at InsideINdianaBusiness.com.

President Trump gaat achter de chip- en semiconductorsector aan. Er komt een tarief van 100 procent, tenzij bedrijven (een deel van) hun productie naar de VS verplaatsen. Een flink dreigement, maar het slaat behoorlijk dood. Aandelen van chipbedrijven van over de hele wereld dalen niet, maar stijgen juist.Deze aflevering kijken we waarom aandeelhouders van ASML, Besi, ASMI en al die andere chippers lak hebben aan Trumps dreigende woorden. Nemen ze hem minder serieus?Serieus zijn wél de heffingen die hij oplegt aan andere landen. Die gaan vandaag in. Een tarief van 19 procent voor Britse producten, tot 50 procent voor spullen uit India. Veel is niet uitgewerkt en er is onduidelijkheid voor ondernemers en overheden. We proberen deze aflevering te kijken hoe het voor jou als belegger uitpakt. Hebben we het ook over een opmerkelijke oproep van Trump (hij had het druk ja). Hij eist per direct het ontslag van de ceo van Intel. Volgens Trump heult de ceo samen met de Chinezen.Verder hebben we het over de crisissituatie in Zwitserland. De president vloog naar Washington, maar tevergeefs. Ze moeten alsnog een torenhoog tarief betalen. Dat is een probleem, want het kost maar liefst een procent van hun BBP.Dit kan je verder verwachten: Sony verhoogt de winstverwachting voor dit jaar. Analisten zijn ook al positief over volgend jaar Aandeel Eli Lilly beleeft een horrordag (ondanks dat ze omzet- en winstverwachting opkrikken) SBM Offshore verhoogt de verwachtingen ook, maar aandeel wordt ook gedumpt AirBNB denkt dat mensen minder op vakantie gaan See omnystudio.com/listener for privacy information.

Meet & Trade - Este 13 de Agosto Tu próxima cita mensual con el MercadoMas info Aquí